A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Summary

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.

Timeline

Start

2024-01-10

Primary completion

2025-09-26

Completion

2025-09-26

Outcome

Met primary endpoint

paper At week 40, for the treatment regimen estimand, all orforglipron doses were non-inferior to dapagliflozin in reducing HbA1c. PMID 42259339 ↗

paper estimated treatment difference versus dapagliflozin was -0·42% (95% CI -0·62 to -0·23), -0·70% (-0·90 to -0·49), and -0·75% (-0·96 to -0·55) PMID 42259339 ↗

release “ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint” lilly.com ↗

Publications

• Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet. 2026 Jul 11;408(10550):125-140. doi: 10.1016/S0140-6736(26)00800-7. Epub 2026 Jun 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dapagliflozin	Small molecule	10 mg	Oral
Subject	Orforglipron	Small molecule	3 mg	Oral
Subject	Orforglipron	Small molecule	12 mg	Oral
Subject	Orforglipron	Small molecule	36 mg	Oral

Indications